Amwell — Third Quarter 2026 Earnings Summary

Amwell reported total revenue of $49.0 million for the third quarter of 2026, surpassing its previous guidance with subscription revenue of $23.9 million and Amwell Medical Group visit revenue of $23.7 million. The company recorded a net loss of $11.0 million and an adjusted EBITDA loss of $3.6 million for the quarter, while achieving a gross margin of 53% across 0.8 million platform visits. Amwell raised its full-year 2026 revenue outlook to a range of $204 million to $206 million and adjusted EBITDA to a range of ($8) million to ($7) million. Additionally, the company reaffirmed its guidance for Amwell Medical Group visits between 1.32 million and 1.37 million and expects to generate positive cash flow from operations in the fourth quarter of 2026.